All the conditions responding to the MP appear to have a similar causation by treatment-resistant cell wall deficient bacteria (CWDB) (see Sidebar). The protocol involves immune modulation, which consists of vitamin D reduction and higher than usual dosages of the angiotensin II receptor blocker, olmesartan (Benicar). These two components of the protocol enable the immune system to kill the CWDB weakened by the third component of the MP, namely, very low dosages of certain antibiotics. (1,3)

Early Results from Ongoing Phase Two Trial

Data

Preliminary results for chronic Lyme disease patients show that of the 51 patients who have been followed on the protocol study site for six to 22 months, 29 are reporting tangible improvement (Reenie Gentile, written communication, July 25, 2006). (3) Marshall (4) also finds significant improvement rates in various other chronic diseases (Table 1). These results probably underestimate the ultimate efficacy of the treatment, because many patients were still in fairly early stages of treatment and were still undergoing strong immunopathology responses to bacterial killing (a.k.a. Jarisch Herxheimer Reactions (1,3)).
Advertisement

Brief Case Histories

The following are brief case histories. (For additional information, please visit http://autoimmunityresearch.org/transcripts/recovery_lax2006.pdf; also see Table 1 for patient improvement rates in other chronic diseases.)

Patient 1 is a 14-year-old boy who has been ill with chronic Lyme disease (with Rickettsial and Chlamydial coinfections) since June 2004. He suffered from chronic severe headaches, debilitating fatigue, a Tourette-like tic occurring every few minutes, blurred/double vision, photophobia, nausea, vertigo, insomnia, and visual tracking problems that prevented him from reading or writing. After 16 months on the MP, all his symptoms have greatly improved, and his tic and visual problems have completely disappeared. He is now able to resume most of his previous activities and continues to improve on the protocol.

Patient 2 is a 58-year-old woman who was diagnosed with Lyme disease in 1999. She had been treated with oral doxycycline in 1999 and 2001. She relapsed after beginning extra vitamin D supplements and increasing sun exposure. Many symptoms have greatly improved in the 29 months since she began the MP, including muscle pain, stiffness and weakness, fatigue, headaches, panic attacks, colitis attacks, nausea, bloating, indigestion, and insomnia. She reports that on the MP, her low back pain has gone from a level 8 to a level 1 on a ten-point scale (attributed to bulging discs at L4 and L5 on MRI), despite decreasing her use of pain medication.

Patient 3 is a 55-year-old female who was diagnosed with rheumatoid arthritis ten years ago. She had previously been on high dose antibiotics (mostly oral, with some IV and IM) for six years prior to the MP and had minimal improvement. Her condition worsened while taking vitamin D prior to the MP (800 to 2400 IU daily over a two-year period). After 29 months on the MP, she reports reduced pain medication use, significantly greater strength and less pain in her hands and upper body, and less fatigue. Recently, her anti-nuclear antibody (ANA) tested negative, after having all 17 prior tests showing elevated levels (usually 1:640 or more).

Patient 4 is a 42-year-old man diagnosed with chronic fatigue syndrome and fibromyalgia. His illness began after he became ill with infectious mononucleosis at the age of 22. Prior to beginning the MP, he could only work two or three days per week and had adverse consequences for days following exercise. He began the MP in March of 2005, and since then, he has had 90-100% resolution of his headaches, light sensitivity, tinnitus, sinus congestion, sore throat, unrefreshing sleep, swelling of fingers and feet, fibromyalgia, and heart palpitations. He has had 70-75% resolution of brain fog, fatigue, and lymph node swelling. He still requires injections of IgG due to a deficiency of lgG3, but the injection interval has increased from an average of 14 days to more than 24 days since commencing the MP. After 22 months on the protocol, he reports feeling markedly better than anytime in the last 20 years and is able to work full time and perform strenuous physical activity.

Patient 5 is a 43-year-old man who had psoriasis since the age of seven, chronic insomnia beginning at the age of 26, and sarcoidosis, diagnosed at the age of 36. His wife had been diagnosed with sarcoidosis several years before. This is in accord with the familial tendency that has been observed among Th1 diseases due to spread of the bacteria among family members. Prior to the MP, numerous treatments had failed to help his psoriasis (e.g., PUVA, steroids, fish liver oil). In contrast, while on the MP, the psoriasis went from 70% coverage of his skin to one percent. The insomnia resolved completely soon after the Benicar was begun. The patient had also suffered from chronic kidney stones, which ceased when he began the protocol. Treatment with the MP has resulted in more than 95% resolution of his symptoms of sarcoidosis (coughing, fatigue, sinusitis, memory problems, muscle aches, etc.), and his chest X-ray is now normal as he continues his fourth year of the MP.